Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

BACKGROUND: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. METHODS: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III s...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, Nicola C., Kumar, Subramanya, Criner, Gerard, Dransfield, Mark, Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kaisermann, Morrys C., Kilbride, Sally, Lange, Peter, Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert, Lipson, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275457/
https://www.ncbi.nlm.nih.gov/pubmed/32503599
http://dx.doi.org/10.1186/s12931-020-01398-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275457/
https://www.ncbi.nlm.nih.gov/pubmed/32503599
http://dx.doi.org/10.1186/s12931-020-01398-w

Ejemplares similares